Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.99)
# 2,891
Out of 4,847 analysts
108
Total ratings
30%
Success rate
-4.14%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XGN Exagen | Maintains: Overweight | $8 → $7 | $7.39 | -5.28% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.26 | +58.73% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $13.54 | +25.55% | 6 | May 14, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $18.89 | +32.35% | 9 | May 6, 2025 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $12 → $9 | $5.31 | +69.49% | 11 | Apr 1, 2025 | |
| SMTI Sanara MedTech | Reiterates: Overweight | $46 | $29.33 | +56.84% | 6 | Mar 26, 2025 | |
| ELUT Elutia | Reiterates: Overweight | $8 | $1.95 | +310.26% | 10 | Mar 7, 2025 | |
| AXGN Axogen | Reiterates: Overweight | $24 | $11.36 | +111.27% | 3 | Mar 5, 2025 | |
| MDXG MiMedx Group | Reiterates: Overweight | $13 | $6.48 | +100.62% | 3 | Feb 27, 2025 | |
| CERS Cerus | Reiterates: Overweight | $4 | $1.44 | +177.78% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $9 | $7.53 | +19.52% | 7 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.49 | +100.67% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.86 | +258.36% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $7.83 | +104.47% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $6.78 | +106.49% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $96 | $82.51 | +16.35% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.05 | +233.33% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.54 | +363.91% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.99 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.81 | +77.94% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.60 | +1,336.20% | 2 | Aug 18, 2023 |
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $7.39
Upside: -5.28%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.26
Upside: +58.73%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $13.54
Upside: +25.55%
SI-BONE
May 6, 2025
Reiterates: Overweight
Price Target: $25
Current: $18.89
Upside: +32.35%
Nano-X Imaging
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $5.31
Upside: +69.49%
Sanara MedTech
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $29.33
Upside: +56.84%
Elutia
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.95
Upside: +310.26%
Axogen
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $11.36
Upside: +111.27%
MiMedx Group
Feb 27, 2025
Reiterates: Overweight
Price Target: $13
Current: $6.48
Upside: +100.62%
Cerus
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.44
Upside: +177.78%
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $7.53
Upside: +19.52%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.49
Upside: +100.67%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $5.86
Upside: +258.36%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $7.83
Upside: +104.47%
Oct 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $6.78
Upside: +106.49%
Oct 15, 2024
Initiates: Neutral
Price Target: $96
Current: $82.51
Upside: +16.35%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.05
Upside: +233.33%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.54
Upside: +363.91%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.99
Upside: -
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $2.81
Upside: +77.94%
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.60
Upside: +1,336.20%